Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-03-06 pm EST			5-day change	1st Jan Change
115.79 ^USD	-0.24%		-6.49%	+10.00%

Mar. 06	Top pharma companies racing to launch a weight-loss pill	RE
Mar. 04	Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer	RE

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Published on 02/05/2026 at 07:05 am EST

S&P Capital IQ

MERCK & CO., INC.

-0.24%

Merck announced that Health Canada has approved ENFLONSIA®? (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants born during or entering their first RSV season. ENFLONSIA®?

is a monoclonal antibody (mAb) that can help provide protection for up to five months--typical of an RSV season. The Health Canada approval marks an important milestone in expanding RSV prevention options for newborns and infants across Canada. Timing of availability may vary across provinces and territories and will depend on factors including provincial and territorial reimbursement programs. Health Canada's approval is supported by results from Merck's clinical development program, including the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) and the Phase 3 SMART trial (MK-16 54-007).

Latest news about Merck & Co., Inc.

Mar. 06	Top pharma companies racing to launch a weight-loss pill	RE
Mar. 04	Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer	RE
Mar. 03	Merck & Co., Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM
Mar. 03	Tempus AI, Merck Collaborate on AI-Driven Precision Medicine	MT
Mar. 03	Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating	MT
Mar. 02	Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating	MT
Mar. 02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
Mar. 02	Merck's Potential Renal Cancer Combos Show Significant Improvement in Meeting Primary Endpoints	MT
Feb. 28	Merck & Co Inc says FDA sets PDUFA date of June 19, 2026 for Welireg and Keytruda	RE
Feb. 28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
Feb. 28	Merck says Welireg plus Lenvima reduces risk of disease progression by 30%	RE
Feb. 28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
Feb. 27	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Feb. 27	Merck to lay off 154 employees	RE
Feb. 27	Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial	MT

Chart Merck & Co., Inc.

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Mar. 16 - Ex-dividend date - 0.85 USD

More about the company